Methacholine chloride - Generic Drug Details

What are the generic drug sources for methacholine chloride and what is the scope of freedom to operate?

Methacholine chloride is the generic ingredient in one branded drug marketed by Methapharm and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for methacholine chloride. One supplier is listed for this compound.

Summary for methacholine chloride

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	79
Clinical Trials:	13
What excipients (inactive ingredients) are in methacholine chloride?	methacholine chloride excipients list
DailyMed Link:	methacholine chloride at DailyMed

Recent Clinical Trials for methacholine chloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
China-Japan Friendship Hospital	PHASE4
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	PHASE4
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	N/A

See all methacholine chloride clinical trials

Pharmacology for methacholine chloride

Drug Class	Cholinergic Receptor Agonist
Mechanism of Action	Cholinergic Agonists

Medical Subject Heading (MeSH) Categories for methacholine chloride

Bronchoconstrictor Agents

Miotics

Muscarinic Agonists

Parasympathomimetics

Anatomical Therapeutic Chemical (ATC) Classes for methacholine chloride

V04CX	Other diagnostic agents
V04C	OTHER DIAGNOSTIC AGENTS
V04	DIAGNOSTIC AGENTS
V	Various

US Patents and Regulatory Information for methacholine chloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Methapharm	PROVOCHOLINE	methacholine chloride	FOR SOLUTION;INHALATION	019193-001	Oct 31, 1986		RX	Yes	Yes
Methapharm	PROVOCHOLINE	methacholine chloride	FOR SOLUTION;INHALATION	019193-002	Aug 29, 2016		DISCN	Yes	No

Market Dynamics and Financial Trajectory for Methacholine Chloride

Last updated: February 16, 2026

Overview
Methacholine chloride is a cholinergic agonist used primarily in diagnostic testing for asthma. Its market is driven by respiratory testing needs, regulatory status, and competition from alternative diagnostics.

Market Size and Growth
The global respiratory diagnostics market was valued at approximately $7.2 billion in 2021 and is projected to grow at a CAGR of 6.3% through 2028 [1]. Although specific data for methacholine chloride is limited, its share within inhalation provocation tests accounts for an estimated 15-20% of the diagnostic segment.

Key Market Drivers

1. Increased prevalence of respiratory diseases: Asthma affects over 300 million people globally, with a rising trend due to urbanization and pollution [2].
2. Regulatory approvals: Many countries, including the US and EU members, approve methacholine for diagnostic purposes, supporting its market presence.
3. Advancements in testing protocols: Enhanced safety protocols and improved delivery methods have facilitated broader clinical adoption.

Market Challenges

1. Safety and administration concerns: Methacholine inhalation tests carry risks of bronchospasm, limiting use to trained professionals and controlled environments.
2. Availability of alternatives: Spirometry and other non-invasive diagnostics are increasingly replacing methacholine testing.
3. Generic competition and pricing: The drug is off-patent in many jurisdictions, leading to price erosion and market commoditization.

Regulatory and Patent Landscape

• No recent Patent Protection: Methacholine chloride is off-patent in major markets since the early 2000s.
• Regulatory Variance: Its approval status varies; it remains a standard test in the US (FDA-approved) and Europe (CE-marked).
• Future regulatory changes could impact access, especially if safer or more precise alternatives emerge.

Financial Trajectory and Investment Outlook

• Historical Revenue: As a diagnostic reagent, revenues are modest, estimated at less than $50 million globally (based on industry reports) [3].
• Expected Trends: Market revenues are expected to decline gradually due to substitution by newer diagnostics. CAGR projections suggest a 2-3% decrease over the next five years without significant new indications or formulations.
• Potential Growth Areas: Adoption in emerging markets and continued standard use in established markets maintain a baseline revenue stream. Investment in formulations that improve safety or ease of use could support renewal of interest.

Competitive Environment

• Dominant suppliers include Sigma-Aldrich and Merck, offering standardized methacholine chloride solutions.
• Product differentiation remains limited; buyers prioritize safety profiles and regulatory compliance over brand or formulation.

Key Market Players	Company	Market Share	Notable Attributes
Sigma-Aldrich	Largest	Global distribution, reliability
Merck	Significant	Broad portfolio, regulatory compliance
Others	Niche	Smaller regional providers

Outlook and Strategic Considerations

• The demand for methacholine chloride is expected to decline as respiratory diagnostics shift.
• Manufacturers could explore niche applications or formulations with enhanced safety.
• Investment hinges on regulatory stability and the ongoing need for provocation testing in clinical practice.

Key Takeaways

• The drug's market is relatively stable but faces decline due to competition and safety concerns.
• Revenue is modest and expected to decrease gradually without innovation.
• Regulatory approvals support continued use, but future growth is uncertain.
• Market shares remain divided among a few established players, with limited room for new entrants.
• Opportunities exist in emerging markets and in developing safer formulations.

---

FAQs

1. What are the primary applications of methacholine chloride?
It is used in bronchial provocation tests to diagnose asthma by assessing airway hyperresponsiveness.

2. Why is the market for methacholine chloride declining?
Because of safety concerns, the availability of alternative diagnostics like spirometry, and the expiration of patents, leading to generic pricing.

3. Are there regulatory barriers to the use of methacholine chloride?
Not generally. It remains approved in key markets, but regulatory scrutiny may increase if safety issues or new alternatives emerge.

4. Can investment in methacholine chloride yield growth?
Limited growth prospects exist without product innovation or targeting emerging markets, given the decline in diagnostic reliance.

5. What factors could reverse its declining trend?
Development of safer formulations, new diagnostic indications, or integration into multi-parameter testing platforms could sustain demand.

---

References
[1] MarketsandMarkets. "Respiratory Diagnostics Market." 2022.
[2] Global Asthma Report. Global Initiative for Asthma, 2021.
[3] Industry Reports, 2022.